Peripheral Inflammation as a Biomarker of Disease Activity in Relapsing-Remitting MS

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Biomarker Discovery

Background:

• Relapsing-remitting multiple sclerosis (RRMS) is a central nervous system autoimmune disease characterized by neurological relapses and inflammation.
• Peripheral inflammatory markers are increasingly recognized as noninvasive predictors of RRMS disease activity and progression.
• This study investigated correlations between specific peripheral inflammatory biomarkers and disease metrics in RRMS patients.

Purpose of the Study:

• To examine the correlations between disease activity and peripheral inflammatory biomarkers in RRMS patients.
• To assess the relationship between interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), and serum neurofilament light chain (sNfL) with clinical and radiographic measures of RRMS.
• To explore the potential of these biomarkers in personalizing therapeutic approaches.

Main Methods:

• A prospective observational study involving 250 RRMS patients over 12 months.
• Clinical evaluation using the Expanded Disability Status Scale (EDSS) and 12-month MRI scans were performed.
• Peripheral blood samples were analyzed for inflammatory markers (IL-6, TNF-α, hs-CRP, ESR) and sNfL.

Main Results:

• Elevated levels of IL-6, TNF-α, and sNfL were observed and positively correlated with EDSS scores and MRI lesion burden (p < 0.05).
• MRI revealed a decrease in inflammatory lesions but an increase in black T1 holes, indicating ongoing neurodegeneration.
• The study identified significant associations between peripheral biomarkers and RRMS disease parameters.

Conclusions:

• Serum neurofilament light chain (sNfL), IL-6, and TNF-α are valuable markers reflecting inflammatory disease activity in RRMS.
• These biomarkers demonstrate associations with clinical and radiographic findings, potentially aiding in personalized treatment strategies for RRMS.
• The findings support the use of peripheral inflammatory markers for monitoring and managing RRMS.